Asset profile

Cannabidiol (Epidiolex) · Epidiolex

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved — Epilepsy

Regulatory approval supersedes design-level evidence grading — the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

How the evidence outlook works ↗

Upcoming events

(11 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (2)
September 2026 (1)
Phase 2Multiple SclerosisActive not recruiting
Est. primary completion 2026-09 · NCT06261489 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2026 (1)
Phase 3Early PsychosisRecruiting
Est. primary completion 2026-12 · NCT04411225 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2027 (5)
May 2027 (1)
Phase 3Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, HR+ Breast Cancer, AI-related Musculoskeletal PainNot yet recruiting
Est. primary completion 2027-05 · NCT06787118 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

August 2027 (1)
Phase 2Multiple Sclerosis, Sleep, PainRecruiting
Est. primary completion 2027-08-30 · NCT05269628 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2027 (1)
Phase 2HIV, Cannabis, THC, Neuroinflammatory Disease, Neuroinflammatory Response, MicrobiomeRecruiting
Est. primary completion 2027-10-31 · NCT05514899 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2027 (1)
Phase 3EpilepsyRecruiting
Est. primary completion 2027-11 · NCT07668856 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2027 (1)
Phase 2SchizophreniaActive not recruiting
Est. primary completion 2027-12 · NCT02926859 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2028 (3)
January 2028 (1)
Phase 2Breast Carcinoma, Chemotherapy-Induced Peripheral Neuropathy, Colon CarcinomaRecruiting
Est. primary completion 2028-01-07 · NCT06731894 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

February 2028 (1)
Phase 3Psychosis, First Episode Psychosis, Psychotic Disorders, Psychotic EpisodeNot yet recruiting
Est. primary completion 2028-02 · NCT06778564 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2028 (1)
Phase 3Treatment Resistant Psychosis, PsychosisNot yet recruiting
Est. primary completion 2028-09 · NCT07326124 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2029 (1)
December 2029 (1)
Phase 3Clinical High Risk for Psychosis (CHR), Clinical High Risk for Psychosis, Clinical High Risk for Developing PsychosisNot yet recruiting
Est. primary completion 2029-12-01 · NCT07434973 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.